Clinical Trials Directory

Trials / Terminated

TerminatedNCT02129426

Comparison of Outcomes During MRI Sedation With Midazolam-dexmedetomidine Versus Ketamine-dexmedetomidine

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
21 (actual)
Sponsor
University of Louisville · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will compare 2 different sedation drugs (Ketamine and Midazolam) when they are used with another sedating medicine called Dexmedetomidine for MRI sedation. This study hopes to measure the impact each drug has on what happens during and after MRI sedation with Dexmedetomidine

Detailed description

The will be a randomized, double-blind, prospective study. All patients referred to UCSS for brain MRI and for whom dexmedetomidine would otherwise be the sedation regimen of choice will be eligible for enrollment. The investigators propose to limit the study to patients undergoing only brain MRI as these studies are of a predictable length (25-30 minutes); therefore the sedation regimen can be more easily standardized. Parents of eligible patients would be approached prior to or during the pre-sedation assessment and told about the study and, if they agree to enroll, informed consent would be obtained. Assent will be obtained from children 7 years of age and greater, if they are otherwise developmentally capable of giving assent. The goal is to enroll 50 subjects (25 per treatment group) which would be sufficient to detect a 25% or greater difference in the mean maximal heart rate or blood pressure decrease from baseline between the 2 groups. Following consent, subjects would be randomized to be sedated with either midazolam-dexmedetomidine or ketamine-dexmedetomidine and, upon achieving an appropriate depth of sedation, undergo their MRI. Monitoring during the MRI and subsequent recovery would occur in compliance with the current Norton Children's Hospital Sedation policy. Recovery-related behavior would be assessed using the Pediatric Anesthesia Emergence Delirium Scale.

Conditions

Interventions

TypeNameDescription
DRUGKetamineSedation medication
DRUGMidazolamSedation medication
DRUGDexmedetomidineSedation medication

Timeline

Start date
2014-08-01
Primary completion
2018-03-01
Completion
2018-03-01
First posted
2014-05-02
Last updated
2021-07-14
Results posted
2021-07-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02129426. Inclusion in this directory is not an endorsement.